Date:3/12/2009

42 55 ---------------------- 5,402 5,908 Property, plant and equipment, net 493 379 Commercial instruments, net 132 164 Purchased technology and trademarks, net 1,058 1,529 ---------------------- 7,085 7,980 ---------------------- ---------------------- Liabilities Current liabilities Accounts payable and accrued liabilities 540 379 Deferred revenue 322 150 Convertible notes payable 2,172 2,008 ---------------------- 3,034 2,537 ---------------------- Shareholders' Equity Common shares 2,524 2,524 Other equity 5,716 5,606 Deficit (4,189) (2,687) ---------------------- 4,051 5,443 ---------------------- 7,085 7,980 ----------------------
'/>"/>

SOURCE Spectral Diagnostics Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
2. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
3. Spectral announces third quarter 2008 results
4. Spectral to bring anti-sepsis therapy to the U.S. market
5. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
8. Spectral and Toray expand collaboration to include new geographic territories
9. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
10. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
11. Spectral announces 2007 financial results